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tient costs were signiﬁcantly higher in PD patients (PD $10,687
vs. MC $8,083 (p < 0.05)), especially associated with compres-
sion fractures, heart murmurs, and spinal stenosis. Inpatient
costs (PD $7045 vs. MC $7514), and prescription costs (PD
$5312 vs. MC $4844) were comparable. CONCLUSIONS: This
study is the ﬁrst to link higher treatment costs with increased
prevalence of co-morbidities associated with PD.
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OBJECTIVES: The cost of treating fractures has a signiﬁcant
impact on Medicare expenditures, totalling in the billions of
dollars annually. The expected cost of treatment for electrical
and ultrasound bone stimulators in the concomitant conserva-
tive treatment of stable nonunion fractures was assessed to iden-
tify the least costly stimulator. METHODS: Treatment pathways
for ﬁve different bone stimulators—Exogen®, Physio-Stim®Lite,
OL1000 Bone Growth Stimulator, OrthoPak®, and EBI Bone
Healing System®—were modelled using a decision tree (TreeAge
Data v3.0.13). Treatment failures were assumed to require
surgery. Probabilities of treatment success came from published
literature, manufacturers’ data, and patient registry data. Cost
data came from published literature and Durable Medical 
Equipment Regional Carriers (DMERCs). For each stimulator,
the expected cost of treating a nonunion fracture was calculated
by folding back the decision tree. One-way sensitivity analyses
were performed by varying all probabilities by ±0.20 and all
costs by ±50%. A Monte Carlo simulation was conducted to
determine the optimal bone stimulator for a hypothetical cohort
of 10,000 patients. The analysis was undertaken from the per-
spective of United States Centers for Medicare and Medicaid Ser-
vices. RESULTS: Exogen® had the lowest expected cost ($6610), 
followed by Physio-Stim®Lite ($8714). Sensitivity analyses
demonstrated expected costs were sensitive to the probability of
success: Exogen® would have the lowest expected cost if its
probability of success were at least 0.745, while OL1000 would
have the lowest expected cost if its probability of success were
at least 0.84. The Monte Carlo simulation showed that Exogen®
was the optimal stimulator for 85% of patients, Physio-
Stim®Lite for 14%, and EBI Bone Healing System® for 1%.
CONCLUSIONS: Exogen® was the least costly bone stimulator
for conservatively treated nonunion fractures. Public insurers
should consider the cost beneﬁts of expanding coverage for
Exogen® to include concomitant conservative treatment of
stable non-union fractures.
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OBJECTIVES: To assess the medical management and cost of
rachialgia in untreated osteoporotic postmenopausal women 
and identify the cost induced by vertebral fracture. METHODS:
EMERAUDE was a multicenter, prospective, observational study
over 6 months. A total of 113 rheumatologists enrolled 427 non-
treated osteoporotic patients between 65 and 85 years-old suf-
fering from thoracic and/or lumbar rachialgia. A DEXA Bone
Mineral Density measurement and spine x-rays were performed
at the beginning of the study. A central reading of x-rays 
differentiated patients with or without vertebral fracture. 
Clinical data, medical consumptions and management care 
were recorded. RESULTS: We report results about the ﬁrst 195
patients followed during three months. The mean age of patients
was 74 years. A total of 50.3% of patients had a vertebral frac-
ture. Patients with vertebral fracture were older (75.5 years
versus 72.6 years; p = 0.0003) and had a major height loss than
women without vertebral fracture. Rachialgia intensity assessed
by a visual analogical scale (0–100) was higher for women with
vertebral fracture (64.8 versus 59.9; p = 0.008). 46% of women
with vertebral fracture had had a history of a non-traumatic
peripheral fracture against 32% for women without vertebral
fracture (p = 0.045). For the 3 months before inclusion; the mean
medical cost was 1207€ for patient with vertebral fracture (70%
due to hospitalisations) against only 425€ for non-fracture
woman. During the three months after inclusion, the mean cost
of woman with vertebral fracture was 903€, nearly 3 times
higher than the management cost of a non-fracture woman (p =
0.024). CONCLUSION: Our results show that the cost of
women suffering from rachialgia depends on the aetiology.
Rachialgia secondary to a vertebral fracture induce a higher
medical consumption than rachialgia without spinal fracture.
These preliminary results, that need to be conﬁrmed, suggest that
vertebral fracture, with no routine corrective treatment, is 
nevertheless a costly condition.
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OBJECTIVES: Miacalcic was shown to be effective in reducing
pain in patients with osteoporotic vertebral fracture (level od rec-
ommendation A). We performed cost-effective analysis of mia-
calcic in comparison to standard therapy with non-steroid
anti-inﬂammatory drugs or analgetics in patients with osteo-
porotic vertebral fracture accompanied with back pain.
METHODS: Subjects included 28 outpatient postmenopausal
women with history of 1 to 5 vertebral fractures who presented
with back pain. 14pts were treated with miacalcic and 14—with
standard therapy. The length of miacalcic treatment was 2 weeks,
the length of follow-up was 3 months. Visual analog scale was
used to assess pain and QUALEFFO-41 to measure quality of
life. The direct and indirect costs of treatment were calculated.
At the start the main clinical characteristics were similar in both
groups. RESULTS: Miacalcic group showed shorter period of
acute pain (7.6 days vs 15.8 days), lower VAS at 2nd week, better
quality of life according to QUALEFFO-41, more patients free
of pain (63% vs 32%), P < 0.05. Although direct costs were
higher in miacalcic (4452 vs 847 rouble), indirect costs were
lower than in controls (1325 vs 4421 rouble). CONCLUSIONS:
Miacalcic is cost-effective in treatment of pain in vertebral frac-
ture osteoporotic patients.
